United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

colorama pharmaceuticals ltd - fludroxycortide - cutaneous cream - 125microgram/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

colorama pharmaceuticals ltd - fludroxycortide - cutaneous ointment - 125microgram/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

typharm ltd - fludroxycortide - impregnated dressing - 4microgram/1square cm

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

typharm ltd - fludroxycortide - cutaneous cream - 125microgram/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

typharm ltd - fludroxycortide - cutaneous ointment - 125microgram/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - fludroxycortide - cutaneous cream - 125microgram/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - fludroxycortide - cutaneous ointment - 125microgram/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - fludroxycortide - cutaneous cream - 125microgram/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - fludroxycortide - cutaneous ointment - 125microgram/1gram

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - ivabradine hydrochloride, quantity: 5.39 mg (equivalent: ivabradine, qty 5 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; maltodextrin; colloidal anhydrous silica; glycerol; hypromellose; iron oxide yellow; iron oxide red; macrogol 6000; titanium dioxide - treatment of chronic stable angina,symptomatic treatment of chronic stable angina due to atherosclerotic coronary artery disease in patients with normal sinus rhythm and heart rate at or above 70 bpm, who are unable to tolerate or have a contraindication to the use of beta-blockers, or in combination with atenolol 50mg once daily when angina is inadequately controlled.,treatment of chronic heart failure,treatment of symptomatic chronic heart failure of nyha classes ii or iii and with documented left ventricular ejection fraction (lvef) less than or equal to 35% in adult patients in sinus rhythm and with heart rate at or above 77 bpm, in combination with optimal standard chronic heart failure treatment.